25I-NBOH

Discovery

The structural foundation for 25I-NBOH was laid in 2006, when researchers at Purdue University demonstrated that attaching an N-arylmethyl group to 2C-class phenethylamines increases 5-HT₂A binding affinity by up to 300-fold.^[2] The NBOMe series (N-2-methoxybenzyl) entered research chemical markets around 2010–2011 as potent psychedelic agents; the NBOH series (N-2-hydroxybenzyl), distinguished by a free phenol group in place of the methoxy, followed shortly after. The precise date of 25I-NBOH's first synthesis is not documented in the peer-reviewed literature.

Forensic identification and market presence

25I-NBOH was first scientifically identified in seized blotter papers from Brazil in 2017, with individual dose loads ranging from 300 to 1,000 µg.^[3] A critical analytical complication emerged: the compound degrades to its parent phenethylamine 2C-I under standard gas chromatography conditions,^[3][6][7] meaning it was likely present in earlier seizures but systematically misidentified. Market reliability remains poor — one documented case found powder labeled as "25I-NBOH" actually contained 25E-NBOH combined with a synthetic cathinone stimulant, with no 25I-NBOH present.^[4]

Scheduling and scientific characterization

Regulatory action has proceeded on a jurisdiction-by-jurisdiction basis, generally lagging behind the more documented 25I-NBOMe. Louisiana scheduled 25I-NBOH in June 2013,^[8] Sweden followed in August 2015,^[8] and Brazil added it to its controlled substances list around the same period.^[3] The publication of formal pharmacological data in 2017–2018^[9][10] transitioned the compound from an analytically identified market substance to a scientifically profiled tool compound.

Structural class

25I-NBOH belongs to the substituted phenethylamine family, specifically the 25x-NBOH series. Its parent compound is 2C-I (2,5-dimethoxy-4-iodophenethylamine), a psychedelic phenethylamine first documented by Alexander Shulgin.citation needed The defining modification is the addition of a 2-hydroxybenzyl group to the amine nitrogen — a change that increases 5-HT₂A receptor binding affinity by up to 300-fold.^[2]

The NBOH scaffold differs from the closely related NBOMe series by a single functional group: NBOH carries a free hydroxyl (phenol), while NBOMe carries a methoxy group (anisole). This distinction affects thermal stability, analytical detection, and how the body metabolizes each compound.^[10]

Molecular properties

The molecule comprises a 2,5-dimethoxyphenethylamine core bearing an iodine atom at the 4-position and an N-(2-hydroxybenzyl) group. The iodine accounts for roughly 31% of the total molecular weight and influences how the compound fits within the 5-HT₂A binding pocket. The 2,5-dimethoxy substitution pattern is essential for full psychedelic activity: removal of either methoxy group markedly reduces potency in animal models beyond what binding data alone would predict.^[11]

Stereochemistry

25I-NBOH possesses no chirality centers and exists as a single achiral species. No stereochemical considerations apply to its activity.

Physical properties and analytical detection

No published data exist for the melting point, solubility, or long-term stability of 25I-NBOH. The compound is typically distributed as a hydrochloride salt.citation needed

The defining physical characteristic is thermal instability. 25I-NBOH breaks down to its parent compound 2C-I under standard gas chromatography conditions, causing systematic misidentification in forensic laboratories.^[3][6][7] Reliable identification requires liquid chromatography methods or chemical derivatization prior to gas chromatography.^[7][6]

Mechanism of action

25I-NBOH is a potent full agonist at serotonin 5-HT₂A and 5-HT₂C receptors, with functional potency comparable to LSD.^[9] It has negligible activity at monoamine transporters, meaning it does not produce stimulant effects through dopamine or norepinephrine reuptake.^[9]

Psychedelic effects are driven by Gq-protein signaling at the 5-HT₂A receptor. Research across a large panel of 5-HT₂A agonists has shown that this Gq pathway — not the alternative β-arrestin2 pathway — is what correlates with psychedelic potential.^[1] The 2,5-dimethoxy groups on the phenethylamine core are structurally essential: removing either one reduces psychedelic activity in animals far more than binding data alone would predict.^[11]

Pharmacokinetics

No human pharmacokinetic data (bioavailability, time to peak, plasma half-life) have been published. All metabolic data come from laboratory microsomal studies.

25I-NBOH is primarily metabolized by the liver enzyme CYP2D6 — a notable difference from 25I-NBOMe, which relies on CYP3A4.^[10] The compound is cleared roughly 1.7 times faster than 25I-NBOMe in microsomal assays.^[10]

This CYP2D6 dependence has practical consequences. Strong CYP2D6 inhibitors — including fluoxetine, paroxetine, and bupropion — may substantially increase 25I-NBOH exposure. Individuals who are genetically CYP2D6 poor metabolizers may experience elevated and prolonged effects.^[10] A secondary glucuronidation pathway may partially offset this variability.

Where it acts

No human neuroimaging data exist for 25I-NBOH. As a potent 5-HT₂A full agonist, it is expected to activate layer V pyramidal neurons in the prefrontal cortex — the primary cellular trigger for serotonergic psychedelic effects. Studies using the close structural analog 25CN-NBOH reveal a dual action in prefrontal neurons: simultaneous excitation of synaptic input and suppression of firing rate through potassium channels.^[12] This push-pull dynamic at the cellular level may explain the coexistence of heightened sensory processing with impaired executive function.

Animal EEG recordings during 25I-NBOH administration show a distinctive slow brainwave pattern (3.5–4.5 Hz) that accompanies behavioral arrest and precedes the head-twitch response.^[13] Nicotine pretreatment modifies this pattern, suggesting cholinergic systems modulate the psychedelic response.^[13]

Theoretical frameworks

The REBUS model (Relaxed Beliefs Under Psychedelics) provides the most relevant interpretive framework: potent 5-HT₂A agonism disrupts the brain's hierarchical processing, weakening top-down predictions and increasing neural flexibility — resulting in the perceptual shifts, enhanced meaning-attribution, and boundary dissolution characteristic of psychedelic states.citation needed The dual excitatory-inhibitory action observed with NBOH compounds^[12] maps onto this framework, potentially representing the cellular substrate of relaxed cortical hierarchies. Whether 25I-NBOH promotes structural neuroplasticity — as proposed for other 5-HT₂A agonists — has not been tested directly.

Toxicity

No lethal dose, therapeutic index, or systematic toxicology data have been published for 25I-NBOH in any species. The acute toxicity profile is inferred from the structural analog 25I-NBOMe and the broader N-benzylphenethylamine class.inferred

Psychological risks

No controlled studies document the psychological risk profile of 25I-NBOH specifically. Acute psychological distress including panic and overwhelming fear is documented in clinical presentations involving related N-benzylphenethylamine compounds.^[17] Agitation, confusion, and excited delirium occur at high doses.^[15]

Hallucinogen persisting perception disorder (hallucinogen-persisting perception disorder) is documented for serotonergic psychedelics as a class but has not been specifically reported for 25I-NBOH.citation needed Community reports describe lingering perceptual or cognitive disturbances lasting 3–12 days. Individuals with personal or family histories of psychotic disorders or bipolar disorder face elevated risk of psychiatric destabilization.

Tolerance and dependence

25I-NBOH is not habit-forming. Like all serotonergic psychedelics, it produces rapid tolerance through downregulation — tolerance builds quickly after a single dose, with full reset estimated at approximately two weeks.inferred This rapid tolerance inherently limits compulsive use.

Cross-tolerance with other serotonergic psychedelics — including LSD, psilocybin, mescaline, and other NBOH/NBOMe compounds — is expected given the shared receptor mechanism. No physical dependence or withdrawal has been described for 25I-NBOH or any member of the NBOH series.

Drug interactions

The primary risk involves serotonergic potentiation. 25I-NBOH is a potent 5-HT₂A/₂C agonist; combining it with any agent that raises serotonin levels creates risk of serotonin syndrome — a potentially life-threatening condition involving dangerously high body temperature, muscle rigidity, rapid heart rate, and agitation.

Tramadol carries dual risk: it blocks serotonin reuptake, potentiating serotonergic toxicity,^[18] and independently lowers the seizure threshold^[15] — compounding the seizure risk associated with high-dose N-benzylphenethylamine use. This interaction is classified as dangerous.

MAOIs, SSRIs, and SNRIs interact through analogous serotonergic mechanisms. MAOIs pose the highest risk by preventing serotonin breakdown; SSRIs and SNRIs block serotonin reuptake.safety citation needed

A separate pharmacokinetic interaction operates through CYP2D6 inhibition. Because 25I-NBOH depends on CYP2D6 for metabolism,^[10] co-administration with strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine) may substantially increase drug levels. Fluoxetine and paroxetine carry compounded risk: they inhibit both CYP2D6 (slowing clearance) and serotonin reuptake (increasing serotonin load).

Cannabis interaction severity is uncharacterized. No direct pharmacological mechanism linking cannabinoid and 5-HT₂A-mediated psychedelia has been established, though community reports describe intensified or destabilized effects.

Contraindications

Contraindication data are derived entirely from class pharmacology; no substance-specific studies exist.inferred

Severe heart conditions constitute an absolute contraindication. The N-benzylphenethylamine class produces rapid heart rate, elevated blood pressure, and vasoconstriction^[15] — dangerous in the setting of coronary artery disease, uncontrolled high blood pressure, or recent stroke.

Seizure disorders are an absolute contraindication. Seizures are a documented complication of severe N-benzylphenethylamine poisoning.^[16][15]

Concurrent serotonergic medications — including MAOIs, SSRIs, SNRIs, and tramadol — are contraindicated due to serotonin syndrome risk.

CYP2D6 poor metabolizer status is a relative contraindication. Individuals with non-functional CYP2D6 genes may experience substantially elevated and prolonged effects.^[10]

Psychotic disorders and bipolar disorder (personal or family history) are relative contraindications.citation needed

As of 2017, 25I-NBOH was not subject to control under United Nations international drug conventions.^[3] National scheduling has proceeded on a jurisdiction-by-jurisdiction basis, generally lagging behind the more documented 25I-NBOMe. The compound's legal status in most countries remains either unscheduled or covered indirectly through structural analog or blanket novel psychoactive substance legislation.